This was conceptualized by the improved knowledge on RA pathogenesis, especially by the demonstration that autoantibodies—particularly ACPA—can be tracked in the sera of patients several years before the onset of clinical arthritis [40]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.